| Budget Amount *help |
¥23,790,000 (Direct Cost: ¥18,300,000、Indirect Cost: ¥5,490,000)
Fiscal Year 2017: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
Fiscal Year 2016: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
Fiscal Year 2015: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2014: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
|
|---|
| Outline of Final Research Achievements |
To develop a specificity-enhanced tumor diagnostic system, we constructed a quantitative and sensitive glycan structure profiling technology based on mass spectrometry. Comprehensive glycoform analysis of 30 serum samples (15 benign prostate hyperplasia (BPH) and 15 prostate cancer, PSA = 4-10 ng/ml) revealed that, among 67 glycan structures, a couple of glycoforms on PSA had highly cancer-specific expressions patterns. Then we established a logistic regression-based diagnostics using expression frequencies of these structures (PSA G-index). Importantly, when we performed a blinded validation test using 15 BPH and 15 prostate cancer samples, PSA G-index allowed classification of all samples into correct clinical groups (sensitivity and specificity were 100%). Thus, PSA G-index could serve as a definitive secondary test for PSA test, leading to significant reduction of false positive diagnosis of prostate cancer.
|
